With Merck’s COVID Antiviral Announcement, Can the Pharma Pipeline Build Treatment Momentum?

 

At the start of the month, pharmaceutical company Merck dropped big news: It has developed a COVID antiviral drug that would cut hospitalization and mortality risks by 50%. In the drug’s study, patients taking the placebo pill saw 14% hospitalization rate and eight deaths, while the trial group with Merck’s drug had only 7% hospitalized and zero deaths.

This appears to be just the tip of the iceberg; Kaiser Health News reports at least three COVID antiviral candidates, including Merck’s, going through late-stage clinical trials, meaning a variety of COVID drugs could be on patient’s prescriptions here soon. What’ll be some of the positive domino effects to come from approval of COVID antivirals, not only on the pharmaceutical production pipeline, but on the general population’s health? Ira Leiderman, managing director of the healthcare practice at Cassel Salpeter & Co., gave MarketScale his take on the coming treatments.

Follow us on social media for the latest updates in B2B!

Image

Latest

Career success
A CEO’s Blueprint for Career Success: Leading with Love to Drive Performance and Culture
March 10, 2026

Leadership right now feels heavier than it did just a few years ago. Teams are stretched, expectations are high, and many employees are quietly disengaged. In fact, Gallup’s 2025 U.S. data shows that only about 31% of employees are actively engaged at work, leaving the majority feeling disconnected or indifferent. For CEOs and senior…

Read More
employer-sponsored apprenticeships
The Degree That Pays You Back: How Employer-Sponsored Apprenticeships Are Rewriting Higher Ed
March 9, 2026

Higher education is under pressure. Over the past few years, public confidence in the value of a four-year degree has declined significantly, with fewer Americans expressing a strong belief that traditional higher education delivers a worthwhile return on investment. At the same time, employers consistently report that graduates lack job-ready skills—particularly the “durable skills”…

Read More
Denial Data
Turning Denial Data Into Action: How Healthcare Organizations Can Fight Back Against Payer Denials
March 5, 2026

Healthcare providers across the U.S. are facing a growing wave of claim denials that is putting pressure on already strained hospital finances. Industry research from the American Hospital Association shows that nearly 15% of medical claims submitted to private payers are initially denied, forcing hospitals and health systems to spend about $19.7 billion annually attempting…

Read More
Jabra
ISE 2026: Jabra Unveils Scalable Room Solutions for the Hybrid Workplace
March 5, 2026

At ISE 2026, Jabra highlighted how meeting technology is evolving to support the realities of hybrid work, where the experience must be equally effective for people inside and outside the room. In a conversation with Craig Durr, Chief Analyst and Founder of The Collab Collective, Jabra’s VP of Video Product Olly Henderson explained that…

Read More